Novo Nordisk Bets on Oral Wegovy to Expand Weight-Loss Market Reach
Published on 01/13/2026 at 12:03 | Redaktion boerse-global.de
In a strategic pivot aimed at capturing a broader patient base, Novo Nordisk is aggressively promoting a new oral version of its weight-loss drug, Wegovy. The shift, moving beyond reliance on injectable treatments, was detailed by CEO Mike Doustdar at the recent J.P. Morgan Healthcare Conference. The core question for investors is whether this pill can successfully unlock a significantly larger segment of the mass market.
Since assuming the CEO role in August 2025, Mike Doustdar has been reshaping the company’s narrative. The central pillar of this new direction is the U.S. launch of an oral Wegovy formulation, explicitly designed to tap into a previously underserved demographic. A key Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
